Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Therapeutic Advances in Medical Oncology|March 17, 2025
Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective studyQi-An Wang, I-Lin Tsai, Chien-Yu Lin, et al.
Thoracic Cancer|July 6, 2019
Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort studyPing-Chih Hsu, John Wen-Chang Chang, Chun-Chieh Wang, et al.
Clinical & Translational Immunology|August 31, 2023
Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanomaJohn Wen-Cheng Chang, Chien-Jung Huang, Wen-Kuan Huang, et al.
JACC. Cardiooncology|July 12, 2022
Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted TherapiesDong-Yi Chen, Jia-Rou Liu, Chi-Nan Tseng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort StudyDong-Yi Chen, Lai-Chu See, Jia-Rou Liu, et al.
Anticancer Research|April 12, 2012
Comparison of genomic signatures of non-small cell lung cancer recurrence between two microarray platformsJohn Wen-Cheng Chang, Nien-Chih Wei, Hung-Ju Su, et al.
Chang Gung Medical Journal|November 1, 2011
Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanomaPo-Jung Su, Jen-Shi Chen, Chuang-Chi Liaw, et al.
Biomedical Journal|January 27, 2024
Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancerJohn Wen-Cheng Chang, Jia-Juan Hsieh, Chih-Yu Tsai, et al.
Japanese Journal of Clinical Oncology|January 16, 2025
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern AsiaHsiao-Jen Chung, Chihiro Kondoh, Woo Kyun Bae, et al.
Biomedical Journal|November 15, 2013
Cisplatin, tegafur-uracil and leucovorin plus mitomycin C: an acceptably effective and toxic regimen for patients with recurrent or metastatic nasopharyngeal carcinomaChia-Hsun Hsieh, Cheng-Lung Hsu, Cheng-Hsu Wang, et al.
Pageof 12